References
- Lamireau T, Monnereau S, Martin A, Marcotte JE, Winnock M, Alvarez F. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol. 2004; 41:920-5.
- Williams SG, Hayller KM, Hodson ME, Westaby D..Prognosis in cystic fibrosis. N Engl J Med. 1992; 327:1244 5.15.
- Rowe S.M., Miller S., Sorscher E.J. Mechanisms of disease, Cystic fibrosis. N. Engl. J. Med., 2005; 352:1992-2001.
- Guido M, Alves VAF, Balabaud C, Bathal PS, Bioulac-Sage P, Colombari R, et al. Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition. Histopathology. 2019; 74:219–226.
- Padoan R, Cirilli N, Falchetti D, Cesana BM. Risk factors for adverse outcome in infancy in meconium ileus cystic fibrosis infants: a multicenter Italian study. J Cystic Fibrosis 2019; 18:863–868.
- Wyatt J, Baker H, Prasad P, Gong YY, Millson C. Steatosis and fibrosis in patients with chronic hepatitis C. J Clin Pathol. 2004; 57:402–406.
- In ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011; 53:726-36. AST to Platelet Ratio Index (APRI).
- Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013; 158:807-20.
- Betapudi B, Aleem A, Kothadia JP. Cystic Fibrosis and Liver Disease. 2022 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 32310546.
- Jeremy D., Debray D., Beaufrere A., Hillaire S., et al. Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. J Hepatol. 2022; 76(2):420-434.
- Lindblad A., Glaumann H., Strandvik B. A Two-Year Prospective Study of the Effect of Ursodeoxycholic Acid on Urinary Bile Acid Excretion and Liver Morphology in Cystic Fibrosis–Associated Liver Disease. Hepatology. 1998; 27(1):166-74.
- Nascimento F., Nelson S., Ferreira T., Marques C.D.F., Silva L., Souza E.L. Hepatobiliary disease in children and adolescents with cystic fibrosis. J Pediatr. 2018; 94(5):504---510.
- Flass T., Narkewickz M.R. Cirrhosis and other liver disease in cystic fibrosis. Department of Pediatrics University of Colorado School of Medicine and The Pediatric Liver Center, Children’s Hospital Colorado, Aurora, CO, USA, 2012.
- Colombo C., Crosignani A., Assaisso M. Battezzati M., Podda M., Giunta A., Zimmer-Nechemias L., Setchell K.D., Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study, Hepatology, 1992; 15; 677-684.
- Gobato AO, Vasques ACJ, Ribeiro AF, Yamada RM, Hessel G. Prevalence of hepatic steatosis among children and adolescents with cystic fibrosis and its association with nutritional status, Rev Paul Pediatry 2019; 37:435–441.